Will CBD be Controlled as a Narcotic?

Recommendation
12/13 November 2025
How to implement EU-GMP Chapter 8
It is currently intensively discussed how Cannabidiol (CBD) will be regulated in the EU in the future. In Germany, for example, CBD is placed on the market as a nutritional supplement. In Finland, though, CBD is considered a medicinal product. Or will it be treated in the EU as a narcotic again?
According to the 2019 WHO recommendation, CBD preparations should be completely removed from the Single Convention as long as the THC concentration does not exceed 0.2 percent.
CJEU classsifies CBD not as a narcotic
The CJEU concluded in November that a member state may not prohibit the marketing of CBD lawfully produced in another Member State when it is extracted from the Cannabis sativa plant in its entirety and not solely from its fibre and seeds.
The CJEU stated that "it should be recalled that the free movement of goods between Member States is a fundamental principle", and that CBD does not appear to have any psychotropic effect or any harmful effect on human health.
For further information please visit the CJEU Website.
In addition, the Commission on Narcotic Drugs (CND) of the UN will consider the WHO recommendation on cannabis and cannabis-related substances, and decided to vote at its reconvened sixty-third CND session from 2–4 December 2020, in order to preserve the integrity of the international scheduling system.
Related GMP News
02.04.2025BfArM Guideline for the Application for a Licence to Cultivate Cannabis
27.03.2025Can RWD support Medical Cannabis Evalution?
27.03.2025Omission of the German Cannabis Monograph
04.03.2025FDA requests Information on the Use of Cannabis Products in Animals
04.03.2025How to Classify Borderline Products?
30.01.2025FDA seeks Feedback on Opiate Alkaloid Content of Poppy Seeds